# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Susan B. Anthony (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI014-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harold Pemberton, MD
- Calendar frame: modern shifted

## What we are working on

- Breathlessness and ankle swelling after travel threaten her lecture schedule **S**
- Does not want to be kept in bed or slowed down by treatment **S**

## Your goals

- Reach euvolemia with no ankle edema and a stable dry weight within three months. Target: 2026-06-29. Recorded outcome: Dry weight 56 kg; furosemide changed to as-needed use. **S**
- Improve the KCCQ-12 overall summary score by at least 15 points by the three-month review. Target: 2026-06-29. Recorded outcome: KCCQ-12 rose from 52 to 70. **S**
- Lower blood pressure below 130/80 by the six-month review without orthostatic symptoms. Target: 2026-09-28. Recorded outcome: Blood pressure 126/72; no dizziness on standing. **S**
- Resume a full speaking and travel schedule by the six-month review. Target: 2026-09-28. Recorded outcome: Back to lecturing twice a month with a travel weight plan. **S**

## What we agreed to do

- Treat congestion with furosemide and start empagliflozin for HFpEF; move to as-needed furosemide guided by daily weights once euvolemic. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Add low-dose spironolactone for HFpEF with blood pressure above target once potassium and kidney function are stable. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Cardiology referral to confirm the diagnosis, review the echocardiogram, and look for specific causes such as amyloidosis or valve disease. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023) **S**
- Check a basic metabolic panel and magnesium one to two weeks after starting or changing diuretic, SGLT2 inhibitor, or mineralocorticoid antagonist therapy, then every three to six months; KCCQ-12 every three to six months. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Daily weights, sodium moderation, a written travel plan for weight gain, and continued daily walking; refer to cardiac rehabilitation if exercise tolerance plateaus. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**
- Pneumococcal and RSV vaccination and a yearly high-dose influenza vaccine to lower the risk of respiratory infection in heart failure. Guideline: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, heart failure monograph (2026) **S**

## Follow-up

- 2026-03-16: Primary care visit for breathlessness on exertion and ankle swelling **S**
- 2026-03-30: Two-week heart failure medication safety check, echocardiogram, and cardiology consultation **S**
- 2026-06-29: Three-month heart failure and blood pressure review **S**
- 2026-09-28: Six-month heart failure review **S**
- 2026-10-19: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
